These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 29249395)

  • 1. Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT.
    Duperret EK; Wise MC; Trautz A; Villarreal DO; Ferraro B; Walters J; Yan J; Khan A; Masteller E; Humeau L; Weiner DB
    Mol Ther; 2018 Feb; 26(2):435-445. PubMed ID: 29249395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
    Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
    Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
    J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.
    Yang Y; Xu W; Peng D; Wang H; Zhang X; Wang H; Xiao F; Zhu Y; Ji Y; Gulukota K; Helseth DL; Mangold KA; Sullivan M; Kaul K; Wang E; Prabhakar BS; Li J; Wu X; Wang L; Seth P
    Hum Gene Ther; 2019 Sep; 30(9):1117-1132. PubMed ID: 31126191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
    Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W
    Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy.
    Jeon D; Hill E; Moseman JE; McNeel DG
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma.
    Kos S; Lopes A; Preat V; Cemazar M; Lampreht Tratar U; Ucakar B; Vanvarenberg K; Sersa G; Vandermeulen G
    PLoS One; 2019; 14(5):e0217762. PubMed ID: 31150505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.
    Ren Z; Guo J; Liao J; Luan Y; Liu Z; Sun Z; Liu X; Liang Y; Peng H; Fu YX
    Clin Cancer Res; 2017 Jan; 23(1):193-203. PubMed ID: 27354469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.
    Pai CS; Simons DM; Lu X; Evans M; Wei J; Wang YH; Chen M; Huang J; Park C; Chang A; Wang J; Westmoreland S; Beam C; Banach D; Bowley D; Dong F; Seagal J; Ritacco W; Richardson PL; Mitra S; Lynch G; Bousquet P; Mankovich J; Kingsbury G; Fong L
    J Clin Invest; 2019 Jan; 129(1):349-363. PubMed ID: 30530991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function.
    Clavijo PE; Friedman J; Robbins Y; Moore EC; Smith E; Zauderer M; Evans EE; Allen CT
    Cancer Immunol Res; 2019 Feb; 7(2):282-291. PubMed ID: 30514791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade.
    D'Alise AM; Leoni G; Cotugno G; Troise F; Langone F; Fichera I; De Lucia M; Avalle L; Vitale R; Leuzzi A; Bignone V; Di Matteo E; Tucci FG; Poli V; Lahm A; Catanese MT; Folgori A; Colloca S; Nicosia A; Scarselli E
    Nat Commun; 2019 Jun; 10(1):2688. PubMed ID: 31217437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
    Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
    Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.
    Liu L; Wang Y; Miao L; Liu Q; Musetti S; Li J; Huang L
    Mol Ther; 2018 Jan; 26(1):45-55. PubMed ID: 29258739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.
    Pico de Coaña Y; Choudhury A; Kiessling R
    Trends Mol Med; 2015 Aug; 21(8):482-91. PubMed ID: 26091825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
    Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
    Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-γ Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1/CTLA-4 Blockade.
    McNamara MJ; Hilgart-Martiszus I; Barragan Echenique DM; Linch SN; Kasiewicz MJ; Redmond WL
    Cancer Immunol Res; 2016 Aug; 4(8):650-7. PubMed ID: 27262113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.
    Yan J; Pankhong P; Shin TH; Obeng-Adjei N; Morrow MP; Walters JN; Khan AS; Sardesai NY; Weiner DB
    Cancer Immunol Res; 2013 Sep; 1(3):179-189. PubMed ID: 24777680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitors in Organ Transplant Patients.
    Kittai AS; Oldham H; Cetnar J; Taylor M
    J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
    Maxwell R; Jackson CM; Lim M
    Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.